This morning, Johnson & Johnson (NYSE: JNJ) announced plans to conduct Ebola vaccine trials on human volunteers starting early January 2015. This Ebola vaccine program, developed at its Janssen Pharmaceutical Company, consists of a two-step injection regimen. The first shot primes the immune system for attack against the virus and the second; taken two months later, boost its response.
This regimen was discovered during Johnson & Johnson’s collaborative research with the National Institute of Health where they combined Janssen’s preventative vaccine with one from Danish’s pharmaceutical company, Bavarian Nordic.
Also read: Air bag maker Takata declares bankruptcy